Soligenix Inc., trading as SNGX on NASDAQ, is advancing in the dermatology sector with SGX302, a synthetic hypericin therapy for mild-to-moderate psoriasis. Early phase 2a trial results indicate promising safety and efficacy, positioning SGX302 as a potential well-tolerated treatment for psoriasis. Soligenix aims to capitalize on the growing $67 billion market opportunity by expanding its presence in dermatology, with ongoing trials potentially leading to regulatory approval and commercialization, highlighting the company's dedication to addressing unmet medical needs in rare diseases.